Navigation Links
British Scientists condemn changes in regulation of Homeopathy

According to top scientific institutions in Britain, patients will be put at risk by alterations in the regulation of homeopathic medicines. Besides, the system// permitting homeopathic medicines to make medical claims is being opposed by hundreds of doctors and scientists.

As the House of Lords discusses the new rules, the statement signed by these doctors and scientists has been released. However, according to the drug regulatory agency, the new regulations will benefit patients.

The Medicines and Healthcare products Regulatory Agency (MHRA) introduced new regulations in September that permit homeopathic preparations to indicate the disorder that they can be used for.

In a statement, the Royal College of Pathologists said they were "deeply alarmed" that the regulation of medicine had "moved away from science and clear information for the public". The Medical Research Council said claims should not be made about efficacy of products without "rigorous and objective evidence". And the BioSciences Federation warned the MHRA's decision was of "extreme concern" adding "it seems in this case that the MHRA has bowed to industry pressure".

The Physiological Society, the British Pharmacological Society, the Society for Applied Microbiology, the Royal Society and the Academy of Medical Sciences are among the 12 national societies that has raised concerns over safety of the patient and correctness of the information.

According to Sense about Science that has been gathering views on this topic, 600 doctors and scientists have signed a statement which says homeopathic medicines should not be permitted to make "unsubstantiated health claims" and that the policy is "damaging to patients' best interests".

Implications like the MHRA has been partially prompted by a desire to improve the homeopathic industry have angered the reviewers. According to the MHRA, if the new system were not introduced, the industry ’s expansion would be inhibited.

Lord Dick Taverne, chair of Sense About Science, who is taking part in the House of Lords debate on the regulation change said: "As many of the medical specialists contacting us have pointed out, evidence-based medicine has been a major public gain of the 20th Century.

"This is the first time, since the thalidomide tragedy and the 1968 Medicines Act, that the regulation of medicines has moved away from the science rather than towards it."

But Dr Peter Fisher, clinical director of the Royal London Homeopathic Hospital said: "The regulations just tidy up the situation by saying 'this homeopathic medicine has been traditionally used for' and it brings it into line with the regulations for herbal medicines. "I think it's a bit of a storm in a teacup," he added.

A spokesperson for the MHRA said: "The National Rules Scheme provides a significant opportunity to improve consumer information about the use of homeopathic products on the UK market whilst maintaining rigorous control over their quality and safety.

"The scheme requires that products have patient information leaflets which are regulated to the same standards as conventional medicines, ensuring that they are clear and comprehensive."
GYT
'"/>




Related medicine news :

1. Designer baby for British couple
2. British Authorities Seize Spurious Drugs
3. Collaborations planned between British Organization and Indian health care industry
4. British Healthcare Mission Explores Partnership Possibilities With Indian Healthcare Sector
5. British Women Flies to India for Treatment of Breast Cancer
6. Sharp Increase In Morning-After Pill Sales Among British Women
7. British company developing ‘Safer Cigarettes
8. British man Recovered from HIV
9. British medical education suffers shortage of bodies
10. Relief For British MS Patients: Cannabis-Based Oral Spray
11. British Scientists Doubt Delhi Doctor’s Stem Cell Claim
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/21/2017)... ... July 21, 2017 , ... ... students improve their chances of acceptance to a residency in a United States ... earned degrees outside the U.S. , According to data released by the ECFMG®, ...
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased ... Vu, PA-C. Beginning July 17, 2017, Ms. Vu will join West Dermatology’s large network ... experience in dermatology, skin cancer , and more. She graduated from the University ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) is ... rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a stem ... With such a challenging diagnosis that requires immediate action, patients and caregivers ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/12/2017)... and Company (NYSE: LLY ) has entered into ... litigation in the U.S. District Court for the Eastern District ... (tadalafil) unit dose patent. This patent was previously set ... agreement, Cialis exclusivity is now expected to end at the ... patent for Cialis is valid and infringed by companies seeking ...
(Date:7/11/2017)... 11, 2017  The global market for liquid biopsy ... $394.1 million in 2016.  Although in early stages, the ... in particular as a result of the gradual shift ... recent introduction of a significant number of new liquid ... of tumor biomarkers to guide treatment decisions. ...
(Date:7/11/2017)... July 11, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... Drug Administration (FDA) has agreed to schedule an End-of-Phase ... IIb trial of its oral insulin capsule ORMD-0801 in ... trial met primary and secondary endpoints by indicating a ...
Breaking Medicine Technology: